Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tryptophan-naphthoquinone (4c) chloride is a research-stage small molecule consisting of a chlorinated 1,4-naphthoquinone moiety conjugated to the amino acid tryptophan. Synthesized using microwave-assisted methods, the compound has been evaluated for its antiproliferative effects in cervical cancer models. It demonstrates potent cytotoxicity against both HPV-positive (SiHa, CaLo) and HPV-negative (C33-A) tumorigenic cell lines, with IC50 values significantly lower than its non-chlorinated counterparts. Its mechanism of action is primarily attributed to the generation of reactive oxygen species (ROS) through redox cycling of the quinone moiety, leading to oxidative stress and potential interference with DNA, RNA, and protein function. The presence of the chlorine atom at the ortho-position enhances its cytotoxic potency by shifting the redox potential toward more positive values, thereby facilitating electron transfer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tryptophan-naphthoquinone (4c) chloride.